Tumor tests may show who will respond to a pituitary tumor drug
Original title: Tumor expression of dopamine receptor and prolactin is associated with acute dopamine agonist response in acromegaly.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors only looked back at records of people already treated, so this is not yet a proven test.
The short version
A test on tumor tissue may show if one common drug is likely to help.
What was studied. Doctors looked back at records of sixty-nine people with newly found acromegaly, a disease caused by a pituitary tumor. Surgery is the main treatment, and it stops the disease for about 50% of people. Each person had a drug test before treatment, and their tumor tissue and blood hormones were checked later.
What they found. Tumors with more of a protein called the dopamine D2 receptor responded better to the drug test. These same tumors also made more of a hormone called prolactin, and blood prolactin was higher too. Tumors with strong prolactin and estrogen receptor signals were smaller and grew less into nearby tissue.
What this means, and what it doesn't
What it could mean: If this holds up, a doctor may be able to check tumor tissue and guess whether this type of drug will help. That could save time trying a drug that will not work. Right now it is a clue for researchers, not a test you can ask for.
What it doesn't mean: This is not a new treatment and not a cure. The team only looked back at old records from one hospital. No new drug or test was tried in a trial here. The authors say it is still unclear how useful this is in everyday care.
Source: PubMed, October 19, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.